Sayeh Dowlatshahi

Sayeh Dowlatshahi

Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

28 September 2020 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
ESEhsan Shabani
Ehsan Shabani
Sayeh DowlatshahiSayeh Dowlatshahi
Sayeh Dowlatshahi
MAMohammad Jafar Abdekhodaie
Mohammad Jafar Abdekhodaie

25 January 2021 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
Sayeh DowlatshahiSayeh Dowlatshahi
Sayeh Dowlatshahi
ESEhsan Shabani
Ehsan Shabani
MAMohammad Jafar Abdekhodaie
Mohammad Jafar Abdekhodaie

24 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SHSamrin F. Habbani
Samrin F. Habbani
Sayeh DowlatshahiSayeh Dowlatshahi
Sayeh Dowlatshahi
NLNathanael Lichti
Nathanael Lichti
MBMeaghan Broman
Meaghan Broman
LTLucy Tecle
Lucy Tecle
Sulma I. MohammedSulma I. Mohammed
Sulma I. Mohammed
Background/Objectives: Cervical cancer (CC) is a significant global health challenge, particularly in low- and middle-income countries (LMICs), where limited access to human papillomavirus (HPV) vaccination and effective CC screening results in a majority of cases and fatalities among women. Moreover, existing vaccines do not target HPV-independent cancers. Current screening methods are expensive and time-consuming, with a limited emphasis on CC protein biomarkers. Therefore, we aimed to validate critical markers that allow the development of affordable point-of-care screening tests for resource-limited settings. Methods: This study first optimized a cell lysis and protein extraction protocol for CC cell lines and clinical cervical swabs. Subsequently, four proteins—topoisomerase II alpha (TOP2A), minichromosome maintenance complex component 2 (MCM2), valosin-containing protein (VCP), and cyclin-dependent kinase inhibitor 2A (p16INK4a)—were quantified in the resulting lysates using enzyme-linked immunosorbent assays, as well as in cervical tumors and squamous intraepithelial lesions (SILs) using immunohistochemistry for further validation. Results: Acetone precipitation allowed for efficient cell isolation, and radioimmunoprecipitation assay buffer yielded the highest protein recovery. VCP and p16INK4a were overexpressed across all cancer cell lines compared to primary cells. All four biomarkers were overexpressed in high-grade SIL (HSIL) swab specimens and tumor samples, including CC subtypes, G1–G3 tumor grades, and HSILs. Lastly, we showed that the proteins could accurately classify swabs and tissue specimens into clinically relevant groups. Conclusions: The quantitative analysis of these biomarkers, along with the subsequent sensitive and specific clinical classification, highlights their potential application in SIL early detection and CC prevention, particularly in LMICs.

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
SHSamrin Farouk Idris Habbani
Samrin Farouk Idris Habbani
Sayeh DowlatshahiSayeh Dowlatshahi
Sayeh Dowlatshahi
MEMonisha Elumalai
Monisha Elumalai
SBScott Charles Bolton
Scott Charles Bolton
LTLucy Teberh Tecle
Lucy Teberh Tecle
SMSulma I Mohammed
Sulma I Mohammed
Cervical cancer is a lethal gynecological malignancy and the fourth most common cancer among women. Most high-grade cervical pre-cancers and cancer cases are linked to infection with high-risk human papillomaviruses (HPV). There is an inequity between high-income countries (HICs) and low- and middle-income countries (LMICs) in cervical cancer burden; according to the World Health Organization, the estimated mortality rate of cervical cancer is 342,000 women worldwide in 2020, and 90% of these women reside in low- and middle-income nations where the human papillomavirus vaccine is unavailable and access to early detection testing are either unavailable or too expensive. This study aims to develop a simple and affordable point-of-care test based on four critical biomarkers for screening high-risk pre-cancer and invasive cervical cancer in collaboration with the biomedical engineering department. A cervical cancer swab will be used in the test. The swab will be placed on a paper-based device that looks for four protein biomarkers critical for the progression of noninvasive cervical cancer into invasive cervical cancer by combining two approaches using proteomics and lateral flow immunochromatography technology. We have validated the markers' expression in cervical cancer and precancerous tissues. The four markers were expressed in squamous cell carcinoma, glassy cell carcinoma, adenocarcinoma, clear cell carcinoma cancer tissues, and the high-grade cervical intraepithelial neoplasia. This point-of-care test will be affordable and implementable, especially in low and middle-income countries. Citation Format: Samrin Farouk Idris Habbani, Sayeh Jalali Dowlatshahi, Monisha Elumalai, Scott Charles Bolton, Lucy Teberh Tecle, Pankti Rajesh Thakkar, Jacqueline C Linnes, Sulma I Mohammed. Point of care test for cervical cancer screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6531.

29 October 2026 in Chemosensors
Verified
Journal Article
Open access
PDF file
Sayeh DowlatshahiSayeh Dowlatshahi
Sayeh Dowlatshahi
ESEhsan Shabani
Ehsan Shabani
MAMohammad Jafar Abdekhodaie
Mohammad Jafar Abdekhodaie
MSMohammad Ali Shafiee
Mohammad Ali Shafiee
Prostate cancer is a neoplastic disease that generally remains asymptomatic until its late-stage emergence. Among the techniques approved to date for prostate cancer diagnosis, prostate-specific antigen (PSA) screening is the most established method for its early detection. Currently, centralized clinical laboratories measure serum PSA using costly, time-consuming, multi-step immunoassays that rely heavily on lab technicians and highly sophisticated equipment. To address this issue, we developed a proof-of-concept, disposable, label-free electrochemical biosensor for rapid detection of PSA-α1-antichymotrypsin complex (PSA-ACT) and free PSA (fPSA) using a single antigen incubation step. The immunosensors were based on HNO3-pretreated pencil graphite electrodes (PGEs) modified with graphene oxide (GO). Antigen concentrations were determined by measuring signals from the [Fe(CN)6]3−/4− redox probe using cyclic voltammetry (CV); the presence of antigen molecules decreased anodic current response at the PGE surface. A log-linear calibration response over 1–1000 ng/mL and an estimated limit of detection (LOD) of 2.48 ng/mL were observed for PSA-ACT, indicating a detection range of 2.48–1000 ng/mL for the tPSA biosensor. The fPSA immunosensor showed a log-linear calibration response over 0.1–1000 ng/mL; however, an analytical LOD below the lowest experimentally evaluated calibrator (0.1 ng/mL) was not determined. Analyses of the biosensors’ performance, selectivity, repeatability, and short-term storage stability, along with a preliminary comparison with commercial enzyme-linked immunosorbent assay (ELISA) kits using real human samples, provided early evidence supporting further development and optimization of these platforms for point-of-care (POC) PSA testing.